Long-Term Prognosis Value of Paravalvular Leak and Patient-Prosthesis Mismatch following Transcatheter Aortic Valve Implantation: Insight from the France-TAVI Registry.
TAVI
mismatch
paravalvular leak
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 Oct 2022
17 Oct 2022
Historique:
received:
02
09
2022
revised:
07
10
2022
accepted:
11
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Transcatheter aortic valve implantation (TAVI) is the preferred treatment for symptomatic severe aortic stenosis (AS) in a majority of patients across all surgical risks. Paravalvular leak (PVL) and patient-prosthesis mismatch (PPM) are two frequent complications of TAVI. Therefore, based on the large France-TAVI registry, we planned to report the incidence of both complications following TAVI, evaluate their respective risk factors, and study their respective impacts on long-term clinical outcomes, including mortality. We identified 47,494 patients in the database who underwent a TAVI in France between 1 January 2010 and 31 December 2019. Within this population, 17,742 patients had information regarding PPM status (5138 with moderate-to-severe PPM, 29.0%) and 20,878 had information regarding PVL (4056 with PVL ≥ 2, 19.4%). After adjustment, the risk factors for PVL ≥ 2 were a lower body mass index (BMI), a high baseline mean aortic gradient, a higher body surface area, a lower ejection fraction, a smaller diameter of TAVI, and a self-expandable TAVI device, while for moderate-to-severe PPM we identified a younger age, a lower BMI, a larger body surface area, a low aortic annulus area, a low ejection fraction, and a smaller diameter TAVI device (OR 0.85; 95% CI, 0.83-0.86) as predictors. At 6.5 years, PVL ≥ 2 was an independent predictor of mortality and was associated with higher mortality risk. PPM was not associated with increased risk of mortality. Our analysis from the France-TAVI registry showed that both moderate-to-severe PPM and PVL ≥ 2 continue to be frequently observed after the TAVI procedure. Different risk factors, mostly related to the patient's anatomy and TAVI device selection, for both complications have been identified. Only PVL ≥ 2 was associated with higher mortality during follow-up.
Sections du résumé
BACKGROUND
BACKGROUND
Transcatheter aortic valve implantation (TAVI) is the preferred treatment for symptomatic severe aortic stenosis (AS) in a majority of patients across all surgical risks.
PATIENTS AND METHODS
METHODS
Paravalvular leak (PVL) and patient-prosthesis mismatch (PPM) are two frequent complications of TAVI. Therefore, based on the large France-TAVI registry, we planned to report the incidence of both complications following TAVI, evaluate their respective risk factors, and study their respective impacts on long-term clinical outcomes, including mortality.
RESULTS
RESULTS
We identified 47,494 patients in the database who underwent a TAVI in France between 1 January 2010 and 31 December 2019. Within this population, 17,742 patients had information regarding PPM status (5138 with moderate-to-severe PPM, 29.0%) and 20,878 had information regarding PVL (4056 with PVL ≥ 2, 19.4%). After adjustment, the risk factors for PVL ≥ 2 were a lower body mass index (BMI), a high baseline mean aortic gradient, a higher body surface area, a lower ejection fraction, a smaller diameter of TAVI, and a self-expandable TAVI device, while for moderate-to-severe PPM we identified a younger age, a lower BMI, a larger body surface area, a low aortic annulus area, a low ejection fraction, and a smaller diameter TAVI device (OR 0.85; 95% CI, 0.83-0.86) as predictors. At 6.5 years, PVL ≥ 2 was an independent predictor of mortality and was associated with higher mortality risk. PPM was not associated with increased risk of mortality.
CONCLUSIONS
CONCLUSIONS
Our analysis from the France-TAVI registry showed that both moderate-to-severe PPM and PVL ≥ 2 continue to be frequently observed after the TAVI procedure. Different risk factors, mostly related to the patient's anatomy and TAVI device selection, for both complications have been identified. Only PVL ≥ 2 was associated with higher mortality during follow-up.
Identifiants
pubmed: 36294438
pii: jcm11206117
doi: 10.3390/jcm11206117
pmc: PMC9604905
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Coll Cardiol. 2021 Mar 9;77(9):1149-1161
pubmed: 33663731
JACC Cardiovasc Interv. 2021 Jul 12;14(13):1466-1477
pubmed: 34238557
J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746
pubmed: 33888385
Eur Heart J Cardiovasc Imaging. 2018 Feb 1;19(2):225-233
pubmed: 28329317
JAMA. 2014 Apr 16;311(15):1503-14
pubmed: 24682026
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
Am J Cardiol. 2017 Feb 15;119(4):618-622
pubmed: 28010874
Eur Heart J Cardiovasc Imaging. 2016 Jun;17(6):589-90
pubmed: 27143783
J Am Coll Cardiol. 2020 Nov 24;76(21):2492-2516
pubmed: 33213729
J Am Coll Cardiol. 2020 Oct 20;76(16):1830-1843
pubmed: 33059828
N Engl J Med. 2012 May 3;366(18):1705-15
pubmed: 22551129
Arch Cardiovasc Dis. 2020 Aug - Sep;113(8-9):534-541
pubmed: 32712203
Circulation. 2020 Jan 28;141(4):260-268
pubmed: 31736332
Circulation. 1978 Jul;58(1):20-4
pubmed: 348341
J Am Coll Cardiol. 2018 Dec 4;72(22):2701-2711
pubmed: 30257798
Circulation. 2014 Apr 1;129(13):1415-27
pubmed: 24566199
J Am Coll Cardiol. 2022 Mar 8;79(9):882-896
pubmed: 35241222
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
J Am Soc Echocardiogr. 2009 Sep;22(9):975-1014; quiz 1082-4
pubmed: 19733789
J Am Coll Cardiol. 2017 Jul 4;70(1):42-55
pubmed: 28662806
JACC Cardiovasc Interv. 2019 Nov 11;12(21):2173-2182
pubmed: 31564593
J Am Coll Cardiol. 2016 Oct 11;68(15):1637-1647
pubmed: 27712776
Circulation. 2020 Jan 28;141(4):243-259
pubmed: 31736356
JACC Cardiovasc Interv. 2021 May 10;14(9):964-976
pubmed: 33958170